JGC
ACET icon

J. Goldman & Co’s Adicet Bio ACET Stock Holding History

J. Goldman & Co’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,568
Closed -$812K – 359
2022
Q3 		$812K Buy
+3,568
New +$906K 0.04% 268
2022
Q2 		– Sell
-1,228
Closed -$392K – 351
2022
Q1 		$392K Buy
1,228
+55
+5% +$12.7K 0.02% 295
2021
Q4 		$328K Buy
+1,173
New +$201K 0.02% 299
2021
Q2 		– Sell
-6,003
Closed -$1.26M – 393
2021
Q1 		$1.26M Sell
6,003
-325
-5% -$74.6K 0.04% 283
2020
Q4 		$1.42M Buy
+6,328
New +$1.3M 0.07% 217

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

J. Goldman & Co's ACET Position: Q4 2022 in Review

J. Goldman & Co sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 3,568 shares — an estimated $812K sold.

J. Goldman & Co first reported a position in ACET in Q4 2020 and held it in 5 quarters. The position peaked at $1.42M in Q4 2020. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • J. Goldman & Co reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • J. Goldman & Co sold 3,568 Adicet Bio shares in Q4 2022, an estimated $812K.
  • J. Goldman & Co first reported a position in Adicet Bio in Q4 2020 and held it in 5 quarters.
  • J. Goldman & Co's Adicet Bio position peaked at $1.42M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.